Caffeine/Metamizole Sodium/Dihydroergotamine Mesylate

咖啡因/安乃近/甲磺酸双氢麦角胺

Report date: 2022/04/19 14:27:31

Base Information

Drug NameCaffeine/Metamizole Sodium/Dihydroergotamine Mesylate

Drug Alias Name甲磺酸双氢麦角胺/咖啡因/安乃近Dihydroergotamine Mesylate/Caffeine/Metamizole SodiumMetamizole Sodium/Dihydroergotamine Mesylate/Caffeine咖啡因/甲磺酸双氢麦角胺/安乃近Dihydroergotamine mesylate/caffeine/dipyrone sodium +[8]

ClassificationSmall molecules

Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine A1 receptor antagonistsSerotonin (5-HT) receptor agonists

TargetsSerotonin (5-HT) receptorAdenosine A1 receptorAdenosine A2a receptor

Therapy Area/IndicationsMigraine Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBrazil

CombinationsYes Dihydroergotamine Mesylate (Shin Nippon Biomedical Laboratories)Caffeine Metamizole Sodium

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAche Laboratorios Farmaceuticos Sa

Active IndicationsMigraine Disorders

Inactive IndicationsN/A

Other Information

ATC CodeN02BB72N02CA51